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Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic
gastrointestinal cancer. Anthracyclines are commonly used in the treatment of upper gastrointestinal cancer. The aim of this study was
to determine the maximum tolerated dose of liposomal, pegylated doxorubicin (Caelyx) in combination with infusional 5-FU/sodium
FA and MMC. Escalating doses of Caelyx (15 – 25 – 30 – 35mgm
 2 corresponding to dose levels I–IV) were applied on days 1 and
29, given to fixed doses of 24-h 5-FU (2000mgm
 2) and sodium FA (500mgm
 2, mixed with 5-FU in one pump) weekly for 6
weeks, and MMC 7mgm
 2 on days 8 and 36. At least three patients were treated at each dose level. A total of 25 patients are
evaluable. No dose-limiting toxicity (DLT) was observed on level I (n¼3). On level II, DLT occurred in three out of five patients
(mucositis and leucopenia). Owing to the early DLTs at this dose, we added a 20mgm
 2 Caelyx dose level (Ia). In total, 17 patients
were treated at this dose level. Among these, only two patients experienced DLT in cycle one and 37 complete cycles have been
administered in association with a low toxicity profile. The median dose intensity was 100% for each drug during the first course and
no treatment delay exceeding 7 days was required. The recommended dose of 4-weekly Caelyx in combination with weekly 24-h 5-
FU/sodium FA and 4-weekly MMC is 20mgm
 2. Preliminary antitumour activity has been observed in patients with pretreated
pancreatic cancer and in untreated gastric cancer.
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Liposomal encapsulation of anticancer drugs has been pursued
intensively during the past number of years. This pharmaceutical
strategy offers the theoretical advantage of increasing drug
efficiency while decreasing toxicity. Pegylated liposomal doxor-
ubicin (Caelyx) is a formulation of doxorubicin encapsulated in
small stealth liposomes that confer a significantly longer half-life to
the drug, and a particular tissue distribution with a high
concentration of the active agent into the tumour. The dose-
limiting toxicities (DLTs) when administered every 3 or 4 weeks at
doses between 40 and 60mgm
 2 are hand–foot skin reaction and
mucositis. In clinical trials, Caelyx has been associated with
significantly less cardiac toxicity and myelotoxicity than free
doxorubicin. Response to Caelyx has been demonstrated against a
broad range of tumours (e.g. Kaposi’s sarcoma, breast, ovarian,
hepatocellular carcinoma, head and neck cancer). It could be
shown that Caelyx can safely be combined with other cytotoxic
drugs such as gemcitabine (Fracasso et al, 2002), vinorelbine
(Gebbia et al, 2002), paclitaxel7cisplatin (Eng et al, 2001;
Mavroudis et al, 2002) and docetaxel (Syrigos et al, 2002).
Only limited data is available on the efficacy of Caelyx in
patients with gastric and pancreatic cancer. Six out of 16 evaluable
patients with pancreatic cancer had stable disease upon treatment
with single agent Caelyx (Halford et al, 2001). In gastric cancer,
single agent Caelyx led to one partial remission and seven cases of
stable disease in 24 evaluable patients (Thomas et al, 2001).
Kagmakis et al (2000) combined 4-weekly Caelyx with bolus 5-
fluorouracil (5-FU) and folinic acid (FA) for salvage treatment of
gastrointestinal tumours. Remission or stable disease was observed
in 60% of patients with pretreated gastric cancer.
Mitomycin (MMC), a quinone-containing antitumour antibiotic,
has been used as a component of chemotherapy for gastrointest-
inal cancers for three decades, and there is evidence of in vitro
synergy between MMC and 5-FU (Sartorelli and Boothe, 1965;
Rusello et al, 1989). When combined with infusional 5-FU,
objective remission rates up to 54% in gastric cancer patients
have been observed (Hofheinz et al, 2002; Hartmann et al, 2003).
In colorectal and pancreatic cancer, protracted infusional 5-FU
plus MMC resulted in a superior response rate in comparison with
5-FU alone, and in an improved failure-free survival in colorectal
cancer (Ross et al, 1997; Maisey et al, 2002).
Received 20 August 2003; revised 23 February 2004; accepted 23
February 2004; published online 13 April 2004
*Correspondence: R-D Hofheinz;
E-mail: ralf.hofheinz@med3.ma.uni-heidelberg.de
British Journal of Cancer (2004) 90, 1893–1897
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lThis study aimed at determining the maximum tolerated dose
and the DLTs of Caelyx in combination with MMC and weekly
infusional 5-FU/FA in patients with upper gastrointestinal cancer.
Sodium FA was used instead of calcium FA because it can be safely
given simultaneously combined with 5-FU in a single infusion
system (Hartung et al, 2001).
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically confirmed gastrointestinal cancer
refractory to at least one chemotherapy regimen were eligible.
They should have been off previous anticancer therapy for at least
4 weeks. Patients with chemotherapy-naı ¨ve gastric cancer were
eligible for inclusion at the recommended dose. Other eligibility
criteria were an ECOG performance status p2, age p75 years, a
life expectancy of at least 3 months and adequate bone marrow
function (leucocyte count 43000ml
 1, platelet count
4100000ml
 1). Adequate renal (serum creatinine p1.4mgdl
 1
or creatinine clearance 460mlmin
 1) and hepatic function
(bilirubin p2mgdl
 1) were required. Left ventricular ejection
fraction (LVEF), assessed by echocardiography, was at least 50% in
eligible patients. Appropriate contraception was required in fertile
patients. All patients provided written informed consent. The
study protocol was reviewed and approved by the local institu-
tional review board (IRB). Treatment was performed according to
the Declaration of Helsinki.
Staging procedures
Before admission to the study, all patients underwent a complete
history, physical examination, ECG and chest X-rays. Cardiac
ultrasonography was carried out to determine the LVEF. A full
blood count with differential and serum chemistry was obtained
within 14 days prior to the start of treatment.
During the study period, weekly blood count monitoring was
performed and serum chemistry was repeated fortnightly. LVEF
was assessed before the initiation of a new treatment cycle.
Toxicities were recorded weekly and graded according to the
Common Toxicity Criteria (CTC) of the National Cancer Institute
(version 2.0).
Although patients were not required to have bidimensionally
measurable disease to enter the study, computed tomography (CT)
scans of the tumour-bearing region were performed within 4 weeks
prior to the start of study treatment. Indicator lesions were
assessed every 8 weeks according to WHO standard criteria.
Treatment schedule, dose escalation and study design
Treatment was given weekly for a total of 6 weeks followed by a 2-
week rest period. Therefore, one course equalled 57 days. The
chemotherapy regimen consisted of a weekly 24-h continuous
infusion of 5-FU 2000mgm
 2 mixed with sodium FA 500mgm
 2
in a portable pump. A central venous port system was implanted in
all patients. Bolus MMC was administered at a dose of 7mgm
 2 on
days 8 and 36. Dexamethasone 8mg was added intravenously to
MMC to prevent pulmonary toxicity. Caelyx was planned as a 1-h
infusion on days 1 and 29 at a dose of 15mgm
 2 (dose level I),
25mgm
 2 (dose level II), 30mgm
 2 (dose level III) and
35mgm
 2 (dose level IV). Owing to DLTs on dose level II in
three out of five patients, another dose level (Ia; Caelyx 20mgm
 2)
was added and approved by the IRB. Dexamethasone 8mg and
clemastine 0.5mg were added routinely to Caelyx after the
observation of allergic reactions in two patients during the first
Caelyx administration. All patients received a standard i.v.
antiemetic prophylaxis (ondansetron or tropisetron) to avoid a
bias on gastrointestinal toxicity.
Dose-limiting toxicity was defined during the first cycle of
chemotherapy (i.e. within the first 57 days), by the occurrence of
one of the following toxicities: grade 4 leucopenia/neutropenia or
thrombocytopenia, symptomatic thrombocytopenia (haemor-
rhage), grade 3 or 4 febrile neutropenia, any Xgrade 3
nonhaematological toxicity except nausea/vomiting. At least three
patients were enrolled per dose level, and the number was
increased to six if DLT occurred in at least one of the first three.
Escalation continued only if DLT was limited to one of six patients.
Escalation halted if DLT occurred in two or more patients.
Maximum tolerated dose (MTD) was defined as the highest dose at
which fewer than two of three or six patients experienced DLTs
during the first course of chemotherapy. Individual dose escalation
was not allowed.
To expand the toxicity data and to assure the safety of this
combination, the recruitment of further patients at the MTD was
provided for in the study protocol. It was planned to also enrol
chemotherapy-naı ¨ve patients with gastric cancer, because even
infusional 5-FU/FA in combination with MMC represents an
effective treatment for these patients, thus making undertreatment
by our investigational regimen unlikely.
Dose intensity at the MTD was determined by dividing the
actually delivered cumulative doses of each drug by the scheduled
cumulative doses.
The overall survival calculation used death due to any reason as
the end point (Kaplan and Maier, 1958).
RESULTS
Patient characteristics
A total of 27 patients were enrolled in the study between July 2001
and November 2002. A total of 25 patients were evaluable for
toxicity according to the protocol. The remaining two patients
were withdrawn from the study for the following reasons: One
patient discontinued therapy after the third administration of 5-FU
due to the development of a bilioma that required surgical
intervention. Another patient experienced an anaphylactic reaction
with bronchospasm, dyspnoea and severe back pain upon the first
administration of Caelyx. In view of this event, therapy was
continued without Caelyx.
The characteristics of all enrolled patients are described in
Table 1. A total of 12 patients with pancreatic cancer had received
at least one previous chemotherapy regimen (gemcitabine75-FU/
FA). Tumour at the primary site, liver metastases as well as
peritoneal carcinomatosis were the most common tumour sites.
After the determination of the MTD, chemotherapy-naı ¨ve
patients with metastatic gastric cancer were treated at the
recommended dose. These patients generally had unresectable
cancer with peritoneal spread of their disease.
Determination of the MTD and dose intensity
Three patients were treated on dose level I (Caelyx 15mgm
 2).
They received a total of eight cycles of chemotherapy (1, 3 and 4
cycles, respectively). Dose-limiting toxicities were neither observed
in cycle 1 nor in any subsequent cycles (Tables 2 and 3). However,
three of five patients on dose level II (Caelyx 25mgm
 2)
experienced DLT between treatment days 14 and 16. One patient
experienced grade 4 leucopenia and two patients grade 3. Grade 3
thrombocytopenia was noticed in three patients. Grade 3
mucositis/stomatitis – with additional diarrhoea in one patient –
was dose limiting in these three patients as well.
Owing to the unexpected early occurrence of DLT at dose level II
and the rather big gap in Caelyx dosage between levels I and II, we
decided to amend the study protocol and include a dose level Ia
(Caelyx 20mgm
 2). The amendment was approved by the IRB.
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DLT (leucopenia grade 4, mucositis grade 4 and diarrhoea grade
3). Therefore, dose level Ia was determined as the MTD. A total of
17 patients were treated at this dose level, including 10 patients
with chemotherapy-naı ¨ve gastric cancer. Only two of these patients
– including the patient mentioned above – developed DLT during
cycle one. In all, 37 complete cycles of chemotherapy were given to
these 17 patients. A total of 16 patients completed cycle 1. A total
of 12 patients have so far received at least two and six patients at
least three complete cycles of chemotherapy.
Dose intensity was calculated for all patients treated at dose level
Ia (Figure 1). A median dose intensity of 100% was reached in
cycle one for each drug (mean dose intensity: 5-FU/FA 94%, MMC
94%, Caelyx 88%). Treatment delays were required only in five
patients during cycle one, which did not exceed 7 days in each
case. The median dose intensities for each drug in cycle two
(n¼12 patients) and three (n¼6 patients) remained high.
Toxicity
Haematological and nonhaematological toxicities are summarised
separately for the first and subsequent cycles in Tables 2 and 3. No
DLT occurred during cycle 1 or subsequent cycles in three patients
treated on dose level I, but DLT was observed in three out of five
patients on dose level II. Each of these patients experienced
leucopenia Xgrade 3, thrombocytopenia grade 3 and gastrointest-
inal toxicities (mucositis grade 3, n¼3 and diarrhoea grade 3,
n¼1). After reducing the Caelyx dose to 20mgm
 2 (level Ia),
DLTs were observed in only two out of 17 patients (12%) in cycle
one. During 37 treatment cycles administered at the recommended
dose level to 17 patients, only three patients (18%) showed DLTs
(cycle one n¼2, cycle three n¼1) (Table 4). No thrombocytope-
nia grade 3 or 4 was observed during cycle one at dose level Ia and
leucopenia Xgrade 3 was documented in only two patients. Caelyx
20mgm
 2 in combination with infusional 5-FU/FA and MMC
proved to be safe and well tolerated even in subsequent courses of
chemotherapy. Interestingly, hand–foot skin reaction – regarded
as a manifestation of overlapping toxicity of infusional 5-FU and
Caelyx – was observed in only four patients treated at the
recommended dose level (24%), although the investigators were
vigilant to the possibility of this adverse event and no prophylactic
measures (e.g. vitamin B6) were in place. In our series, only one
patient required a dose reduction because of hand–foot skin
reaction.
No renal toxicity and no evidence of MMC-induced haemolytic–
uremic syndrome was seen.
Antitumour activity
A total of 17 patients had bidimensionally measurable tumour
masses. Two objective responses (pancreatic cancer and che-
motherapy-naı ¨ve gastric cancer) and two minor remissions
(pancreatic cancers) were observed. Of the 11 patients with
advanced gastric cancer, only three had measurable disease
(partial remission (PR), n¼1 and no change (NC), n¼2). Median
survival in these patients has not yet been reached after a median
follow-up of 9 months, despite the fact that the vast majority of
patients had tumours with unfavourable prognostic characteristics
(irresectable primary and peritoneal carcinomatosis). The group of
Table 1 Patient demographics
Variable No. of patients (%)
Enrolled 27 (100)
Assessable 25 (93)
Median age 63 (range, 38–74)
Gender
Male 16 (59)
Female 11 (41)
Performance status (ECOG)
Median 1
0 1 (4)
1 17 (63)
2 9 (33)
Tumor origin
Pancreatic cancer 12 (44)
Gastric cancer 11 (41)
Cholangiocarcinoma 3 (11)
Cancer of unknown primary (adenocarcinoma) 1 (4)
Prior chemotherapy
None (gastric cancer) 10 (37)
One line 13 (48)
Two lines 4 (15)
Gemcitabine 15 (56)
5-fluorouracil-based (i.v. or oral) 8 (30)
Others (irinotecan, oxaliplatin) 2 (7)
Tumor localisation
Primary 19 (70)
Liver 17 (63)
Lymph nodes 6 (22)
Peritoneal carcinomatosis 10 (37)
Other 2 (7)
i.v.¼intravenous.
Table 2 Haematological toxicity (according to Common Toxicity Criteria) per dose level in cycle one and in subsequent cycles (worst per patient)
Toxicity (no. of patients)
Dose level No. of patients Anaemia Leucopenia Thrombocytopenia
Cycle 1
1 2 3 4 1 2 3 4 1234
I 3 1 1 1 — 1 — — — ————
Ia 17 12 4 — — 1 3 1 1 6 — — —
II 5 2 3 — — — — 2 1 — — 3 —
Cycles 41
1 2 3 4 1 2 3 4 1234
I 2 11—————— 1 — — —
Ia 12 7 5 — — 4 1 1 — 7 — 1 —
I I 2 11—————— — 1 — —
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chemotherapy had a median survival of 6.5 months calculated
from the start of study treatment (i.e. second- or third-line
chemotherapy).
DISCUSSION
Combinations of infusional 5-FU/FA with MMC are commonly
used in gastrointestinal cancer (Hartmann et al, 2003). In gastric
cancer, MMC (10mgm
 2) added every third week to weekly
infusional 5-FU/FA yielded a response rate of 54%, and a median
overall survival of 10.2 months (Hofheinz et al, 2002). Ross et al
(2002) reported the results of a randomised study comparing ECF
(3-weekly epirubicin and cisplatin in combination with protracted
venous infusional (PVI) 5-FU 200mgm
 2 daily) to MCF (MMC
7mgm
 2 every 6 weeks and 3-weekly cisplatin with PVI-5-FU
300mgm
 2 daily). The MCF and ECF regimen resulted in
equivalent response rates and survival, thus confirming the
efficacy of combined infusional 5-FU and MMC in gastric cancer.
For patients with metastatic colorectal cancer, several studies on
combination therapy of MMC and infusional 5-FU in first- or
second-line protocols have been published (e.g. Ross et al, 1997;
Chester et al, 2000; Grumett et al, 2001). Administered as salvage
treatment, the addition of MMC to 5-FU-containing regimens may
overcome resistance to 5-FU.
In both, colorectal and pancreatic cancer, protracted infusional
5-FU plus MMC resulted in a superior response rate in comparison
with 5-FU alone, but this did not translate into a survival
advantage (Ross et al, 1997; Maisey et al, 2002).
Anthracyclines are used in combination regimens in gastric
cancer (e.g. Ross et al, 2002) or pancreatic cancer (e.g. Neri et al,
2002). They formed part of the FAM (5-FU, doxorubicin, MMC)
and FAMtx (5-FU, doxorubicin, methotrexate) regimens, respec-
tively. Either of these combinations was formerly considered
standard treatment in gastric cancer. The FAM has been shown to
be superior to best supportive care in pancreatic carcinoma
(Palmer et al, 1994), although trials have failed to clearly
demonstrate an advantage over single agent 5-FU (Cullinan et al,
1985).
No combination trial with Caelyx and infusional 5-FU7MMC
has been published to date. Based on the outcomes of previous
studies, it seemed rationale to test the combination of Caelyx with
infusional 5-FU, FA and MMC with the aim of identifying a
regimen to deliver 5-FU, MMC and doxorubicin in their
presumably most effective manner: infusional 5-FU modulated
by sodium FA (mixed in one pump), dose-dense MMC and
liposomal pegylated doxorubicin. The phase I study presented here
was designed to evaluate the safety and tolerability of escalating
doses of Caelyx in combination with weekly infusional 5-FU/
sodium FA and 4-weekly bolus MMC. 5-Fluorouracil and MMC
Table 3 Nonhaematological toxicity (according to Common Toxicity Criteria) per dose level in cycle 1 and in subsequent cycles (worst per patient)
Toxicity (no. of patients)
Dose levels No. of patients Nausea/emesis Stomatitis/mucositis Diarrhoea Alopecia Hand–foot skin reaction
Cycle 1
1/2 3 4 1/2 3 4 1/2 3 4 1 2 1 2 3
I3 2 — — — — — 1 — — — — — — —
Ia 17 8 5 — 7 1 1 4 2 — 4 1 4 — —
II 5 1 — — — 3 — — 1 — 1 1 — — 1
Cycles 41
1/2 3 4 1/2 3 4 1/2 3 4 1 2 1 2 3
I2 2 — — 1 — — 1 — — — — — — —
Ia 12 9 — — 5 — — 6 1 — 3 1 2 2 —
II 2 1 — — — — — 1 1 — — 1 — 1 —
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Figure 1 Dose intensity (in percentage) of each compound in patients treated at the recommended dose during cycles one (n¼17), two (n¼12) and
three (n¼6), respectively
Table 4 Toxicity (worst per patient) for all patients treated at dose level
Ia (Caelyx 20mg
 2) according to Common Toxicity Criteria (n¼17
patients; n¼37 cycles)
Toxicity Grade I/II (%) Grade III (%) Grade IV (%)
Anaemia 17 (100) 0 0
Leucopenia 6 (35) 1 (6) 1 (6)
Thrombocytopenia 9 (53) 1 (6) 0
Nausea/emesis 8 (47) 5 (29) 0
Stomatitis/mucositis 7 (41) 1 (6) 1 (6)
Diarrhoea 9 (53) 3 (18) 0
Alopecia 6 (35) — —
Hand–foot skin reaction 4 (24) 0 —
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former studies (Hofheinz et al, 2002; Hartmann et al, 2003) and the
Caelyx dose was escalated.
Four-weekly Caelyx 20mgm
 2 can safely be combined with
weekly infusional 5-FU/sodium FA and 4-weekly MMC. Mucositis
and leucopenia were the dose-limiting side effects. A total of 37
cycles have been applied to 17 patients at the recommended dose
level. Dose-limiting toxicity was observed in only three of these
patients during the first cycle or subsequent cycles. A median dose
intensity of 100% was reached for each drug during cycle one (57
days). Therapy delays were fairly uncommon and did not exceed 1
week. Despite the limited number of patients treated so far with
this combination therapy, we conclude that a high dose intensity
can be achieved in a considerable percentage of patients for
periods of up to 6 months. Neither renal toxicity, haemolytic
uremic syndrome, nor pulmonary toxicity has been observed.
Hand–foot skin reaction, a painful desquamating dermatitis of the
hands and feet, is seen in association with infusional 5-FU as well
as with Caelyx. It has only been observed in 24% of the patients
treated at the recommended dose level in our study. Apparently,
the combination of both drugs at the investigated doses does not
confer a higher incidence of hand–foot skin reaction than either
drug alone. Therefore, it might be speculated that different
pathogenetic mechanisms are involved.
Despite administering an obviously well-tolerated regimen, we
noticed a median survival of 6.5 months in patients with pretreated
pancreatic cancer. This might be biased due to patient selection.
Tumour shrinkage was seen in three of these patients. A total of 10
patients with metastatic gastric cancer, mostly with peritoneal
spread not amenable to objective tumour assessment, have been
treated for first line. One PR and two NC lasting for 8 months were
observed in three patients with measurable disease. The median
survival has not yet been reached.
In conclusion, the established application schedule for the
combination of Caelyx, MMC and weekly 24-h infusional 5-FU/
sodium FA is well tolerated and appears to be active in patients
with upper gastrointestinal cancer. High dose intensity was
achieved in a substantial percentage of patients for several months.
Our current efforts focus on phase II studies in gastric and
pretreated pancreatic cancer.
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